179 related articles for article (PubMed ID: 11245447)
1. Role of the central melanocortin system in cachexia.
Marks DL; Ling N; Cone RD
Cancer Res; 2001 Feb; 61(4):1432-8. PubMed ID: 11245447
[TBL] [Abstract][Full Text] [Related]
2. Differential role of melanocortin receptor subtypes in cachexia.
Marks DL; Butler AA; Turner R; Brookhart G; Cone RD
Endocrinology; 2003 Apr; 144(4):1513-23. PubMed ID: 12639936
[TBL] [Abstract][Full Text] [Related]
3. Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83-132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice.
Joppa MA; Gogas KR; Foster AC; Markison S
Peptides; 2007 Mar; 28(3):636-42. PubMed ID: 17204351
[TBL] [Abstract][Full Text] [Related]
4. Peripheral administration of a melanocortin 4-receptor inverse agonist prevents loss of lean body mass in tumor-bearing mice.
Nicholson JR; Kohler G; Schaerer F; Senn C; Weyermann P; Hofbauer KG
J Pharmacol Exp Ther; 2006 May; 317(2):771-7. PubMed ID: 16436498
[TBL] [Abstract][Full Text] [Related]
5. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome.
Fan W; Boston BA; Kesterson RA; Hruby VJ; Cone RD
Nature; 1997 Jan; 385(6612):165-8. PubMed ID: 8990120
[TBL] [Abstract][Full Text] [Related]
6. The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist.
Markison S; Foster AC; Chen C; Brookhart GB; Hesse A; Hoare SR; Fleck BA; Brown BT; Marks DL
Endocrinology; 2005 Jun; 146(6):2766-73. PubMed ID: 15774557
[TBL] [Abstract][Full Text] [Related]
7. Cachexia: lessons from melanocortin antagonism.
Deboer MD; Marks DL
Trends Endocrinol Metab; 2006 Jul; 17(5):199-204. PubMed ID: 16750633
[TBL] [Abstract][Full Text] [Related]
8. Mutations in the carboxyl terminus of the agouti protein decrease agouti inhibition of ligand binding to the melanocortin receptors.
Kiefer LL; Ittoop OR; Bunce K; Truesdale AT; Willard DH; Nichols JS; Blanchard SG; Mountjoy K; Chen WJ; Wilkison WO
Biochemistry; 1997 Feb; 36(8):2084-90. PubMed ID: 9047307
[TBL] [Abstract][Full Text] [Related]
9. Melanocortin-4 receptor in sheep: a potential site for therapeutic intervention in disease models.
Sartin JL; Wagner CG; Marks DL; Daniel JA; McMahon CD; Obese FY; Partridge C
Domest Anim Endocrinol; 2005 Aug; 29(2):446-55. PubMed ID: 15919173
[TBL] [Abstract][Full Text] [Related]
10. MC4 receptor antagonists: a potential treatment for cachexia.
Foster AC; Chen C; Markison S; Marks DL
IDrugs; 2005 Apr; 8(4):314-9. PubMed ID: 15800806
[TBL] [Abstract][Full Text] [Related]
11. Effect of Agouti-related protein in regulation of the hypothalamic-pituitary-thyroid axis in the melanocortin 4 receptor knockout mouse.
Fekete C; Marks DL; Sarkar S; Emerson CH; Rand WM; Cone RD; Lechan RM
Endocrinology; 2004 Nov; 145(11):4816-21. PubMed ID: 15256492
[TBL] [Abstract][Full Text] [Related]
12. The role of the melanocortin-3 receptor in cachexia.
Marks D; Cone RD
Ann N Y Acad Sci; 2003 Jun; 994():258-66. PubMed ID: 12851324
[TBL] [Abstract][Full Text] [Related]
13. Central administration of peptide and small molecule MC4 receptor antagonists induce hyperphagia in mice and attenuate cytokine-induced anorexia.
Joppa MA; Ling N; Chen C; Gogas KR; Foster AC; Markison S
Peptides; 2005 Nov; 26(11):2294-301. PubMed ID: 16269355
[TBL] [Abstract][Full Text] [Related]
14. Genetic and pharmacologic blockade of central melanocortin signaling attenuates cardiac cachexia in rodent models of heart failure.
Scarlett JM; Bowe DD; Zhu X; Batra AK; Grant WF; Marks DL
J Endocrinol; 2010 Jul; 206(1):121-30. PubMed ID: 20371568
[TBL] [Abstract][Full Text] [Related]
15. Effects of ghrelin on anorexia in tumor-bearing mice with eicosanoid-related cachexia.
Wang W; Andersson M; Iresjö BM; Lönnroth C; Lundholm K
Int J Oncol; 2006 Jun; 28(6):1393-400. PubMed ID: 16685441
[TBL] [Abstract][Full Text] [Related]
16. Assessment of a small molecule melanocortin-4 receptor-specific agonist on energy homeostasis.
Cepoi D; Phillips T; Cismowski M; Goodfellow VS; Ling N; Cone RD; Fan W
Brain Res; 2004 Mar; 1000(1-2):64-71. PubMed ID: 15053953
[TBL] [Abstract][Full Text] [Related]
17. Feeding and behavioural effects of central administration of the melanocortin 3/4-R antagonist SHU9119 in obese and lean Siberian hamsters.
Schuhler S; Horan TL; Hastings MH; Mercer JG; Morgan PJ; Ebling FJ
Behav Brain Res; 2004 Jul; 152(2):177-85. PubMed ID: 15196785
[TBL] [Abstract][Full Text] [Related]
18. Peripheral administration of the melanocortin-4 receptor antagonist NBI-12i ameliorates uremia-associated cachexia in mice.
Cheung WW; Kuo HJ; Markison S; Chen C; Foster AC; Marks DL; Mak RH
J Am Soc Nephrol; 2007 Sep; 18(9):2517-24. PubMed ID: 17687077
[TBL] [Abstract][Full Text] [Related]
19. Anticatabolic properties of melanocortin-4 receptor antagonists.
Madison LD; Marks DL
Curr Opin Clin Nutr Metab Care; 2006 May; 9(3):196-200. PubMed ID: 16607116
[TBL] [Abstract][Full Text] [Related]
20. Food deprivation decreases responsiveness of ventromedial hypothalamic neurons to melanocortins.
Li YZ; Davidowa H
J Neurosci Res; 2004 Aug; 77(4):596-602. PubMed ID: 15264229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
